Abstract Purpose PET with 68 Ga-DOTATOC allows for imaging and quantitative
assessment of somatostatin receptor expression in neuroendocrine tumors (NET). The aim …

Purpose Our aim was to assess the prognostic and predictive value of somatostatin receptor
2 (sstr 2) in neuroendocrine tumors (NETs). Methods We established a tissue microarray …

Simple Summary This article discusses the use of peptide receptor radionuclide therapy
(PRRT) as a key treatment method for advanced, unresectable neuroendocrine tumors. It …

Objectives To compare the diagnostic accuracy of 111 In-pentetreotide-scintigraphy with 68
Ga-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients …

Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology
because these proteins are overexpressed on the cell membranes of different human …

The key for molecular imaging is the use of a radiotracer with a radioactive and a functional
component. While the functional component targets a specific feature of the tumor, the …

We aimed to evaluate 68Ga-DOTATATE PET/CT for the early prediction of time to
progression and clinical outcome after a first cycle of peptide receptor radionuclide treatment …

Abstract Gallium-68 somatostatin receptor (SMSR) positron emission tomography (PET) and
positron emission tomography/computed tomography (PET/CT) are valuable diagnostic …

68Ga-DOTATOC, a somatostatin receptor–targeted ligand, has been used clinically in
Europe over the past decade for imaging neuroendocrine tumors (NETs). It appears to be …

Neuroendocrine tumors (NET) are often metastatic at the time of diagnosis. Metastatic well-
differentiated (G1/G2) NET may display a wide range of behaviors, ranging from indolent to …